New drug delivery system for corneal administration of mitomycin-C

详细信息    查看全文

• 作者：Francisco Irochima Pinheiro ; PhD ; Irami Ara&uacute ; jo-Filho ; PhD ; ^{irami.filho@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Amalia Cinthia Meneses do Rego ; PhD ; Eduardo Pereira de Azevedo ; PhD ; Eryvaldo Socrates Tabosa do Egito ; PhD ; Fernando Or&eacute ; fice ; PhD ; Ac&aacute ; cio Alves de Souza Lima Filho ; PhD
• 刊名：Journal of Cataract & Refractive Surgery
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：42
• 期：8
• 页码：1216-1223
• 全文大小：588 K

文摘

To develop a new corneal release system to deliver optimum amounts of mitomycin-C (MMC) during the perioperative period of photorefractive keratectomy (PRK).

Setting

ra0015">Ophthalmos S/A, São Paulo, Brazil.

Design

ra0020">Experimental study.

Methods

ra0025">An in vitro experimental design was developed for studying a new MMC delivery system at a drug concentration of 0.02%. Whatman sterile filter paper disks with a diameter of 8.0 mm were impregnated with MMC solution. After drying, the disks were placed on agar plates seeded with Staphylococcus epidermidis; this was followed by instillation of a drop of sterile water. After 1 minute, the disks were removed and the plates were incubated for 48 hours at 35°C. The mean volume of the drops delivered from regular eyedrop bottles was determined, and the inhibition zone (in millimeters) was correlated with the amount of MMC loaded onto the disks.

Results

ra0030">Analysis of the inhibition zones produced by MMC indicated that 16 μg was the optimum dose to be incorporated in the disks. The mean volume of a drop delivered from eyedrop bottles was 37.7 μL. One minute after the application of a single drop of a balanced salt solution, the system released an adequate concentration of MMC for PRK.

Conclusion

ra0035">A new delivery system for MMC was successfully developed for application during photorefractive keratectomy.

Financial Disclosure

ra0040">Dr. de Souza Lima Filho is the managing director of Ophtalmos S/A. Drs. de Souza Lima Filho, Irochima Pinheiro, and Oréfice have exclusive rights to intellectual property of this invention secured by a patent application filed with the Instituto Nacional da Propriedade Industrial.